Corbus Pharmaceuticals (CRBP) has received reaffirmed Buy ratings from both H.C. Wainwright and Oppenheimer despite a recent stock decline triggered by disappointing data from Novo Nordisk’s obesity drug. Analysts remain optimistic about Corbus’ diverse pipeline, highlighting the potential of its CRB-913 and CRB-701.
Amazon Prime Video is kicking off the summer season with a lineup that includes the highly anticipated fourth season of “The Boys,” as well as last year’s Oscar winner for Best Picture, “Oppenheimer.” Additionally, the Mean Girls musical remake and the documentary “Federer: Twelve Final Days” will be making their way to the streaming service. For those looking to binge-watch, the drama series “Las Vegas” will be available on Prime Video starting June 1st.
Despite challenges faced by the gaming industry, Oppenheimer remains optimistic about Electronic Arts’ prospects, maintaining its Outperform rating and $150.00 price target. While acknowledging recent underperformance of ‘Apex Legends’ and moderating fiscal year 2025 forecasts, the firm suggests potential catalysts in the latter half of 2024 that could make Electronic Arts an attractive investment compared to its peer Take-Two Interactive. Oppenheimer’s analysis points to the company’s strong market position, portfolio of popular gaming franchises, and strategic positioning as key factors driving its positive outlook.
